Analyst Upgrade: Needham reiterated its buy rating on Tempus AI with a price target of $75. Market observers highlighted the Personalis acquisition as a misunderstood but positive catalyst for long-term growth in the MRD space.
Price Action Concerns: Recent trading showed the stock gapping lower with key support levels between $48 and $44 appearing vulnerable. Discussions focused on whether a break below $31 would invalidate prior bullish setups.
Broader Context: Social media commentary positioned Tempus alongside other health data platforms as building independent intelligence stacks. Sentiment remained engaged with the firm's positioning in AI-driven medical datasets.
Note: This discussion summary was generated from an AI condensation of post data.
Tempus AI Insider Trading Activity
Tempus AI insiders have traded $TEM stock on the open market 58 times in the past 6 months. Of those trades, 0 have been purchases and 58 have been sales.
Here’s a breakdown of recent trading of $TEM stock by insiders over the last 6 months:
- ERIC P LEFKOFSKY (CEO and Chairman) has made 0 purchases and 36 sales selling 1,033,422 shares for an estimated $56,004,902.
- RYAN FUKUSHIMA (CEO, Data) has made 0 purchases and 7 sales selling 66,426 shares for an estimated $3,673,678.
- JAMES WILLIAM ROGERS (Chief Financial Officer) has made 0 purchases and 3 sales selling 32,466 shares for an estimated $1,707,846.
- ANDREW POLOVIN (EVP, Chief Legal Officer) has made 0 purchases and 4 sales selling 27,795 shares for an estimated $1,524,677.
- ERIK PHELPS (EVP, Chief Admin. Officer) has made 0 purchases and 2 sales selling 9,464 shares for an estimated $562,472.
- RYAN M BARTOLUCCI (Chief Accounting Officer) has made 0 purchases and 2 sales selling 7,018 shares for an estimated $352,755.
- JENNIFER A DOUDNA sold 2,673 shares for an estimated $147,015
- THOMAS EDWARD SCHOENHERR (CEO, Diagnostics) sold 1,580 shares for an estimated $69,630
- DAVID R EPSTEIN has made 0 purchases and 2 sales selling 620 shares for an estimated $34,331.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Quiver Alerts
Receive TEM Data Alerts
Get market-moving data, filings, and signals for TEM in real time.
Sign Up
Tempus AI Revenue
Tempus AI had revenues of $348.1M in Q1 2026. This is an increase of 36.12% from the same period in the prior year.
You can track TEM financials on Quiver Quantitative's TEM stock page.
You can access data on TEM stock through the Quiver Quantitative API.
Tempus AI Hedge Fund Activity
We have seen 230 institutional investors add shares of Tempus AI stock to their portfolio, and 184 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- GC WEALTH MANAGEMENT RIA, LLC removed 4,199,843 shares (-63.5%) from their portfolio in Q2 2026, for an estimated $243,296,904
- UBS GROUP AG added 1,750,525 shares (+118.0%) to their portfolio in Q1 2026, for an estimated $79,158,740
- BLACKROCK, INC. added 1,452,220 shares (+19.3%) to their portfolio in Q1 2026, for an estimated $65,669,388
- SUMITOMO MITSUI TRUST GROUP, INC. added 821,490 shares (+23.4%) to their portfolio in Q1 2026, for an estimated $37,147,777
- AMOVA ASSET MANAGEMENT AMERICAS, INC. added 821,490 shares (+23.4%) to their portfolio in Q1 2026, for an estimated $37,147,777
- TWO SIGMA INVESTMENTS, LP removed 792,083 shares (-49.8%) from their portfolio in Q1 2026, for an estimated $35,817,993
- BANK OF AMERICA CORP /DE/ removed 725,709 shares (-63.6%) from their portfolio in Q1 2026, for an estimated $32,816,560
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Tempus AI Government Contracts
We have seen $29,358,042 of award payments to $TEM over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.
Tempus AI Price Targets
Multiple analysts have issued price targets for $TEM recently. We have seen 11 analysts offer price targets for $TEM in the last 6 months, with a median target of $64.0.
Here are some recent targets:
- Gene Mannheimer from Freedom Capital Markets set a target price of $59.0 on 07/01/2026
- Ryan MacDonald from Needham set a target price of $75.0 on 06/01/2026
- Mark Massaro from BTIG set a target price of $80.0 on 06/01/2026
- Yi Chen from HC Wainwright & Co. set a target price of $64.0 on 05/11/2026
- Dan Brennan from TD Cowen set a target price of $68.0 on 05/06/2026
- Tycho Peterson from Jefferies set a target price of $35.0 on 04/13/2026
- Subbu Nambi from Guggenheim set a target price of $60.0 on 03/30/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Read full article here »
View the Zacks #1 Rank List
Tempus AI Stock (TEM) Opinions on Personalis Acquisition and Analyst Upgrades
Analyst Upgrade: Needham reiterated its buy rating on Tempus AI with a price target of $75. Market observers highlighted the Personalis acquisition as a misunderstood but positive catalyst for long-term growth in the MRD space.
Price Action Concerns: Recent trading showed the stock gapping lower with key support levels between $48 and $44 appearing vulnerable. Discussions focused on whether a break below $31 would invalidate prior bullish setups.
Broader Context: Social media commentary positioned Tempus alongside other health data platforms as building independent intelligence stacks. Sentiment remained engaged with the firm's positioning in AI-driven medical datasets.
Note: This discussion summary was generated from an AI condensation of post data.
Tempus AI Insider Trading Activity
Tempus AI insiders have traded $TEM stock on the open market 58 times in the past 6 months. Of those trades, 0 have been purchases and 58 have been sales.
Here’s a breakdown of recent trading of $TEM stock by insiders over the last 6 months:
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Tempus AI Revenue
Tempus AI had revenues of $348.1M in Q1 2026. This is an increase of 36.12% from the same period in the prior year.
You can track TEM financials on Quiver Quantitative's TEM stock page.
You can access data on TEM stock through the Quiver Quantitative API.
Tempus AI Hedge Fund Activity
We have seen 230 institutional investors add shares of Tempus AI stock to their portfolio, and 184 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Tempus AI Government Contracts
We have seen $29,358,042 of award payments to $TEM over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.
Tempus AI Price Targets
Multiple analysts have issued price targets for $TEM recently. We have seen 11 analysts offer price targets for $TEM in the last 6 months, with a median target of $64.0.
Here are some recent targets:
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Read full article here »